Early signs of fatty liver disease to watch for: A clinical guide to subtle symptoms and testing

Early signs of fatty liver disease to watch for include persistent tiredness and discomfort in the upper right side of the abdomen, although many people notice no symptoms at all. Nonalcoholic fatty liver disease, now also called metabolic dysfunction-associated steatotic liver disease, is commonly discovered through blood tests or imaging performed for another reason rather than through a distinctive early warning sign. 1

Why fatty liver disease is often silent

Fatty liver disease develops when excess fat accumulates in the liver. The less inflammatory form, called NAFL or MASL, may involve fat with little or no liver damage, while NASH or MASH includes inflammation and damage that can cause fibrosis, or scarring. The National Institute of Diabetes and Digestive and Kidney Diseases describes NAFLD as a silent disease with few or no symptoms, meaning a person can have substantial disease without feeling unwell. 3

• Absence of symptoms does not rule out fatty liver disease. 1
• Some people remain symptom-free even after cirrhosis develops. 1
• Routine evaluation may identify the condition before symptoms appear. 2

Subtle symptoms worth monitoring

When symptoms occur, fatigue is one of the most frequently described complaints, while discomfort, pressure, or a dull sensation in the upper right abdomen can occur when the liver is enlarged or inflamed. These symptoms are nonspecific and may have many other causes, so they cannot confirm fatty liver disease on their own. Persistent symptoms are more informative when considered alongside weight changes, diabetes, abnormal cholesterol, or other metabolic risk factors. 1

• Unexplained or persistent tiredness may warrant discussion with a clinician. 1
• Upper-right abdominal discomfort can occur with liver enlargement. 3
• Symptoms that come and go still do not establish a diagnosis. 2

Metabolic clues that may come first

Because symptoms are often absent, metabolic health can provide an earlier indication of risk. Higher likelihood is associated with overweight or obesity, insulin resistance or type 2 diabetes, high triglycerides, abnormal cholesterol, high blood pressure, and a large waist size. NIDDK identifies metabolic syndrome as the presence of at least three related traits, including elevated glucose, high triglycerides, low HDL cholesterol, high blood pressure, and increased waist size. 1

• Type 2 diabetes or insulin resistance raises concern for MASLD. 1
• High triglycerides, high LDL cholesterol, or low HDL cholesterol are relevant risk markers. 1
• Physical inactivity, a high-sugar diet, and sugary beverages may contribute to risk. 2

Findings a clinician may detect

A physical examination may reveal an enlarged liver, although this cannot be reliably assessed by self-examination. Clinicians also assess body weight and height to calculate body mass index and may look for signs of insulin resistance, including darkened skin patches over the knuckles, elbows, and knees. An enlarged spleen, fluid accumulation in the abdomen, and muscle loss are more concerning findings associated with cirrhosis rather than typical early fatty liver disease. 2

• Hepatomegaly means an enlarged liver detected during clinical assessment. 2
• Darkened skin patches can be a physical sign of insulin resistance. 2
• Ascites, an enlarged spleen, and muscle loss require assessment for advanced disease. 2

What blood tests and scans can show

Doctors diagnose fatty liver disease using medical history, a physical examination, blood tests, and imaging. Blood testing can identify abnormal liver enzymes or other findings that prompt further evaluation, but normal results do not necessarily exclude fatty liver disease. Imaging can demonstrate fat in the liver, while additional noninvasive tools may help estimate fibrosis. The diagnostic process also considers alcohol intake and other possible causes of liver fat. 2

• Medical history includes metabolic conditions, diet, activity, and alcohol intake. 2
• Ultrasound is used to evaluate hepatic steatosis in primary-care assessment recommendations. 5
• Fibrosis-4 scoring and elastography can support risk stratification when advanced fibrosis is a concern. 4

Signs that suggest more advanced liver damage

Yellowing of the skin or eyes, dark urine, pale stools, abdominal fluid, or spider-like blood vessels should not be treated as typical early signs of simple fatty liver. The supplied clinical information identifies jaundice and other visible changes as indicators that may reflect impaired or advanced liver function. NASH or MASH can progress from inflammation to fibrosis and cirrhosis, which represents permanent scarring and can increase the risk of liver cancer. 3

• Jaundice is generally associated with more advanced liver injury rather than early steatosis. 3
• Dark urine or pale stools should prompt medical assessment for liver or biliary problems. 3
• Cirrhosis may involve ascites, an enlarged spleen, and muscle loss. 2

How risk is assessed in primary care

Assessment is not based on one symptom or one laboratory value. Clinicians review cardiometabolic conditions, examine for physical findings, test for alternative causes, and use imaging or noninvasive fibrosis tools when appropriate. A 2026 American Family Physician review describes a two-step approach that begins with the Fibrosis-4 index and uses vibration-controlled transient elastography or ultrasound-based methods for indeterminate or higher-risk results. 4

• People with diabetes, obesity, or multiple metabolic risk factors may warrant testing. 5
• Cardiovascular disease, chronic kidney disease, and obstructive sleep apnea may coexist with MASLD. 5
• Risk assessment helps distinguish lower-risk fatty liver from possible advanced fibrosis. 4

When symptoms should not be dismissed

Fatigue or upper-right abdominal discomfort alone does not prove fatty liver disease, but persistent complaints combined with obesity, diabetes, high blood pressure, abnormal triglycerides, or cholesterol changes create a stronger reason for clinical review. The main limitation is that symptoms are unreliable: many affected people have none, and other conditions can produce the same sensations. Evaluation should therefore focus on the complete medical history, examination, laboratory findings, and imaging rather than on symptom matching alone. 1

• Do not assume that feeling well means the liver is unaffected. 1
• Do not interpret an isolated abnormal liver enzyme as a diagnosis. 2
• Consider alcohol-associated disease and other causes when liver fat is identified. 2

Sources

1. National Institute of Diabetes and Digestive and Kidney Diseases, Symptoms & Causes of NAFLD & NASH
2. National Institute of Diabetes and Digestive and Kidney Diseases, Diagnosis of NAFLD & NASH
3. National Institute of Diabetes and Digestive and Kidney Diseases, Definition & Facts of NAFLD & NASH
4. American Family Physician, Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management
5. Medical Journal of Australia, Assessment of metabolic dysfunction-associated fatty liver disease in primary care